Dec'04 | Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Income | $154.4M | $175.6M | $173.2M | $172.6M | $198.3M | $238.0M | $284.3M | $300.1M | $408.4M | $454.5M | $482.6M | $642.7M | $783.8M | $1,022.7M | $748.2M | $1,146.8M | $1,628.4M | $1,348.5M | $1,748.5M | $1,534.1M |
Discover the top 20 best undervalued stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued large-cap growth stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Jan 2025.
As of today, Edwards Lifesciences Corporation's last 12-month Operating Income is $1,596.8M, based on the financial report for Sep 30, 2024 (Q3 2024).
Over the last year, Edwards Lifesciences Corporation's Operating Income growth was 0.9%. The average annual Operating Income growth rates for Edwards Lifesciences Corporation have been 20.0% over the past three years, 14.0% over the past five years.
Over the last year, Edwards Lifesciences Corporation's Operating Income growth was 0.9%, which is higher than industry growth of (0.2%). It indicates that Edwards Lifesciences Corporation's Operating Income growth is Good.